Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6751 to 6765 of 7681 results

  1. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued [GID-TAG433]

    Technology appraisal guidance
    Discontinued

  2. Diabetic foot ulcers - new treatments [ID381]

    Discontinued [GID-TAG371]

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development [GID-TA10696] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    In development [GID-TA10766] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Glaucoma - lerdelimumab (CAT-152) [ID383]

    In development [GID-TAG381] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    In development [GID-TA10995] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    In development [GID-TA11004] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued [GID-TAG417]

    Technology appraisal guidance
    Discontinued

  9. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued [GID-TA10429]

    Technology appraisal guidance
    Discontinued

  10. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued [GID-TAG511]

    Technology appraisal guidance
    Discontinued

  11. Macular oedema (diabetic) - pegaptanib sodium [ID452]

    Discontinued [GID-TAG280]

    Technology appraisal guidance
    Discontinued

  12. Serelaxin for the treatment of acute decompensated heart failure [ID673]

    Discontinued [GID-TAG454]

    Technology appraisal guidance
    Discontinued

  13. Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917]

    Discontinued [GID-TA10065]

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued [GID-TA10418]

    Technology appraisal guidance
    Discontinued

  15. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued [GID-TA10452]

    Technology appraisal guidance
    Discontinued